Björn Kull

ORCID: 0000-0001-8190-1625
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Adenosine and Purinergic Signaling
  • Receptor Mechanisms and Signaling
  • Neuroscience and Neuropharmacology Research
  • Pharmacological Receptor Mechanisms and Effects
  • Neurotransmitter Receptor Influence on Behavior
  • Neuropeptides and Animal Physiology
  • Calcium signaling and nucleotide metabolism
  • RNA Interference and Gene Delivery
  • Regulation of Appetite and Obesity
  • Plant Virus Research Studies
  • Plant Disease Resistance and Genetics
  • Immune Cell Function and Interaction
  • Nerve injury and regeneration
  • Cell death mechanisms and regulation
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Organic Light-Emitting Diodes Research
  • Pancreatic function and diabetes
  • Reproductive System and Pregnancy
  • Neurological disorders and treatments
  • Synthesis and Biological Evaluation
  • Eicosanoids and Hypertension Pharmacology
  • Parkinson's Disease Mechanisms and Treatments
  • Inflammatory mediators and NSAID effects
  • Transgenic Plants and Applications
  • Nitric Oxide and Endothelin Effects

Swedish Orphan Biovitrum (Sweden)
2005

Karolinska Institutet
1996-2004

Max Delbrück Center
1997

Max Planck Society
1992

In situ hybridization with cRNA probes showed A<sub>2A</sub> receptor and G<sub>olf</sub> mRNAs to be abundantly expressed in caudate putamen, nucleus accumbens, olfactory tubercle, whereas G<sub>s</sub> mRNA shows a comparatively low expression regions expressing receptors. 49% of the medium-sized neuron-like cells exhibited strong signal for adenosine mRNA, 98% mRNA. contrast, was found only 12% putamen. The coexpression that or studied double hybridization. A large majority (91–95%)...

10.1124/mol.58.4.771 article EN Molecular Pharmacology 2000-10-01

We have characterized the binding of new potent and selective antagonist radioligand [ 3 H]‐5‐amino‐7‐(2‐phenylethyl)‐2‐(2‐furyl)‐pyrazolo[4,3‐ e ]‐1,2,4‐triazolo[1,5‐ c ]pyrimidine, H]‐SCH 58261, to human cloned A 2A adenosine receptors. In Chinese hamster ovary (CHO) cells transfected with receptor, 58261 specific (about 70%) was rapid, saturable, reversible proportional protein concentration. The kinetic K D value 0.75 n M . Saturation experiments showed that labelled a single class...

10.1038/sj.bjp.0701119 article EN British Journal of Pharmacology 1997-05-01

10.1007/pl00005319 article EN Naunyn-Schmiedeberg s Archives of Pharmacology 1999-01-01

Abstract The intrastriatal infusions of ‘naked’ small interfering RNA (siRNA) targeted to dopamine D 1 receptors (1.0–10.0 nmol over 3 days) did not reduce receptor messenger levels or protein, assessed by [ 125 I] SCH 23982 binding in intact rats. This was contrast results vitro where a 76% reduction ligand could be observed. Conclusion: suggest that synthetic siRNA, when applied directly rat brain, is capable inducing interference.

10.1046/j.1365-201x.2003.01188.x article EN Acta Physiologica Scandinavica 2003-09-19

The coupling of the four defined types adenosine receptors to G proteins and consequent activation effector pathways is briefly summarized. It pointed out that are able influence many cellular systems, and, in particular, α β,γ-subunits may activate different signalling either act synergistically or antagonistically cell. Because physiologically plays role a modulator, particular emphasis placed on interactions with parallel pathways. Drug Dev. Res. 39:262–268, 1996. © 1997 Wiley-Liss, Inc.

10.1002/(sici)1098-2299(199611/12)39:3/4<262::aid-ddr5>3.0.co;2-p article EN Drug Development Research 1996-11-01

Abstract This overview will focus on recent data from our laboratory. The four cloned human adenosine receptors stably transfected into Chinese hamster ovary cells were studied with respect to signaling via cyclic AMP and mitogen‐activated protein (MAP) kinases. Adenosine acted as a full agonist at all the when increases (A 2A or A 2B receptors) decreases 1 3 in accumulation studied. was approximately equipotent , receptors, but 50 times higher concentrations needed receptors. potency of...

10.1002/ddr.1124 article EN Drug Development Research 2001-01-01
Coming Soon ...